According to GlobalData’s medical device pipeline database, 20 Sustained Release Injectable Systems devices are in various stages of development globally. GlobalData’s report Sustained release injectable systems provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 17 are in active development, while the remaining three are in an inactive stage of development. There are 16 products in the early stages of development, and the remaining one is in the late stages of development.
Drug delivery devices are used for administration of drug compounds in effective ways. Sustained-release injectable systems are a type of drug delivery system that releases medication over a prolonged period of time. This is in contrast to traditional injectables, which deliver the medication all at once. It uses a microsphere or nanoparticle formulation that are made up of tiny particles containing the medication. The particles are designed to release the medication slowly over time. They also use polymer-based formulation where the polymer slowly degrades over time, releasing the medication in a controlled manner. Sustained-release injectables can be used to deliver a variety of medications, including hormones, antibiotics, and chemotherapy drugs.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Sustained Release Injectable Systems pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Sustained Release Injectable Systems devices. Overall, most of these Sustained Release Injectable Systems pipeline devices are being developed by private entities.
Key players involved in the active development of Sustained Release Injectable Systems include IntraGel Therapeutics, EyePoint Pharmaceuticals, Re-Vana Therapeutics, University of South Florida, University of Texas Rio Grande Valley, Origin Endoscopy, Rebel Medicine, AmacaThera and Emergent BioSolutions.
For a complete picture of the developmental pipeline for Sustained Release Injectable Systems devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
